First Wave BioPharma Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

GRDX$5.35+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, there unto duly authorized.


	FIRST WAVE BIOPHARMA, INC.

March 29, 2024
	By:	/s/ James Sapirstein
		Name: James Sapirstein
		Title: Chief Executive Officer

	By:	/s/ Sarah Romano
		Name: Sarah Romano
		Title: Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the registrant and in the capacities held on the dates indicated.

Signature	Title	Date

/s/ James Sapirstein	Chief Executive Officer and Chair of the Board of Directors	March 29, 2024
James Sapirstein	(principal executive officer)

/s/ Sarah Romano	Chief Financial Officer	March 29, 2024
Sarah Romano	(principal financial officer and accounting officer)

/s/ Edward J. Borkowski	Director	March 29, 2024
Edward J. Borkowski

/s/ Charles J. Casamento	Director	March 29, 2024
Charles J. Casamento

/s/ Terry Coelho	Director	March 29, 2024
Terry Coelho

/s/ Alastair Riddell	Director	March 29, 2024
Alastair Riddell

/s/ Jack Syage	Director	March 29, 2024
Jack Syage

/s/ Chaitan Khosla	Director	March 29, 2024
Chaitan Khosla

-102-

First Wave BioPharma, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.